Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 study is evaluating obinutuzumab versus mycophenolate mofetil for childhood onset idiopathic nephrotic syndrome; the trial is currently active but not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood Idiopathic Nephrotic Syndrome

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)
• Gazyva (Obinutuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Childhood Idiopathic Nephrotic Syndrome | Phase 3 | Status: ACTIVE_NOT_RECRUITING